Comparative Pharmacology
Head-to-head clinical analysis: MUCINEX versus MUCINEX DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUCINEX versus MUCINEX DM.
MUCINEX vs MUCINEX DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating its removal.
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
600 mg orally twice daily (extended-release); for immediate-release: 200 mg orally three times daily or 400 mg orally twice daily.
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
1-2 hours (terminal elimination half-life); clinical context: rapid clearance requires frequent dosing to maintain mucolytic effect.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Renal: approximately 50-60% as unchanged drug (guaifenesin) and metabolites; minor biliary/fecal elimination (<10%).
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Category C
Category C
Expectorant
Expectorant/Antitussive Combination